LA JOLLA, Calif. — Gene therapy with a recombinant AAV2-hRPE65 vector may be safe and effective in patients with Leber congenital amaurosis due to RPE65 mutations, according to a study presented here.
“LCA is a congenital retinal dystrophy [that] is caused by mutations in at least 13 different genes and about 10% of people in the U.S. have because they lack the protein RPE65,” Tim Stout, MD, PhD, MBA, said at the American Ophthalmological Society meeting.
Full Story »
Personalize your page!
Register for Healio to get content tailored to your specialty and areas of interest.
It’s FREE and only takes one minute.